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Dopaminergic and endothelin systems participate in the
control blood pressure by regulating sodium transport in the
renal proximal tubule. Disruption of either the endothelin
B receptor (ETB) or D3 dopamine receptor gene in mice
produces hypertension. To examine whether these two
receptors interact we studied the Wistar–Kyoto (WKY) and
spontaneously hypertensive (SHR) rats by selectively infusing
reagents into the right kidney of anesthetized rats. The D3
receptor agonist (PD128907) caused natriuresis in WKY rats
which was partially blocked by the ETB receptor antagonist.
In contrast, PD128907 blunted sodium excretion in the SHRs.
We found using laser confocal microscopy that the ETB
receptor was mainly located in the cell membrane in
control WKY cells. Treatment with the D3 receptor antagonist
caused its internalization into intracellular compartments
that contained the D3 receptors. Combined use of D3 and
ETB antagonists failed to internalize ETB receptors in cells
from WKY rats. In contrast in SHR cells, ETB receptors were
found mainly in internal compartments under basal
condition and thus were likely prevented from interacting
with the agonist-stimulated, membrane-bound D3 receptors.
Our studies suggest that D3 receptors physically interact
with proximal tubule ETB receptors and that the blunted
natriuretic effect of dopamine in SHRs may be explained,
in part, by abnormal D3/ETB receptor interactions.
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The kidney is endowed with two local hormonal systems that
play major roles in the regulation of sodium transport across
the renal proximal tubule (RPT), namely the dopaminergic
and endothelin systems.1–7 Endothelin regulates epithelial
sodium transport through two receptor subtypes (ETA
(endothelin A) and endothelin B (ETB)).5–7 Although it is
still not known if the ETB receptor is the subtype responsible
for the actions of endothelin at the RPT, there is evidence that
endothelin-1 inhibits Naþ–Kþ ATPase activity in this
nephron segment.8 It is generally accepted, however, that
dopamine, which is synthesized in and secreted from RPT
cells, decreases RPT sodium transport by inhibiting Naþ /Hþ
exchanger isoform-3 (NHE3), sodium bicarbonate cotrans-
porter (NBCe1), Naþ–Pi cotransporter type-2 (NaPi2),
and Naþ–Kþ ATPase activities, through D1 and D3 receptors
in this nephron segment.1–4 Although these two hormonal
systems are involved in renal sodium excretion, little is
known regarding the physiological interactions of renal
dopamine and endothelin in the control of sodium excretion
in vivo.
Dopamine receptors are classified into D1- and D2-like
subtypes based on their structure and pharmacology. There
are two D1-like receptors (D1 and D5) and three D2-like
receptors (D2, D3, and D4), which are expressed in mam-
malian kidneys.1–4 Approximately, 50% of basal sodium
excretion is mediated by the paracrine action of renal
dopamine exerted on D1 receptor.
1–4 In the rat kidney, the
major D2-like receptor located in RPTs is the D3 receptor.
9,10
Disruption of the D3 receptor gene in mice produces
hypertension, which is associated with a decreased ability
to excrete a sodium load.11 Stimulation of the D3 receptor,
synergistically with D1 receptor, induces natriuresis and
diuresis in Wistar–Kyoto (WKY) rats.12,13 However, the
mechanisms of D3 receptor-mediated natriuresis are incom-
pletely understood.
Endothelin B receptors are expressed in RPT cells.14 In
uninephrectomized spontaneously hypertensive rats (SHRs)
treated with deoxycorticosterone acetate and fed a high-salt
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diet, and in humans with essential hypertension, ETB
receptor activation may function to counter-regulate the
increase in blood pressure.15–17 Naturally occurring or
induced deletion of the ETB receptor gene and chronic
pharmacological blockade of the ETB receptor in rats result
in salt-sensitive hypertension.17,18 We hypothesize that a
D3/ETB receptor interaction promotes sodium excretion in
WKY rats, but not in SHRs. The current study employed
a direct renal stimulation of D3 receptor with PD128907, a
selective D3 receptor agonist, to evaluate its effects on renal
sodium excretion in WKY rats and SHRs. We suggest that D3
receptors regulate RPT ETB receptors by physical receptor
interaction and that the impaired natriuretic effect of the
D3 receptor agonist in SHRs may be explained, in part, by
an aberrant D3/ETB receptor interaction.
RESULTS
D3 and ETB receptor localization in kidney
D3 receptor staining was found mostly in the subapical
areas of the S1, S2, and S3 (with the strongest signal) seg-
ments of the proximal tubules in WKY rats and SHRs.
The ETB receptor was expressed in the proximal tubules,
especially at the brush border membranes of the S3 segment,
similar to those noted with the D3 receptor. No staining
was seen when the antibodies were preadsorbed with
the immunizing peptide (Figure 1a–d). D3 and ETB recep-
tor colocalization (laser confocal microscopy) was evident
in all proximal tubules of the kidney in WKY rats
(Figure 1e).
Stimulation of renal D3 receptors increases sodium
excretion in WKY rats, which was impaired in SHRs
To determine the effect of D3 receptors on sodium excretion,
varying dosages of PD128907 (0.5, 1.0, 5.0, and 10.0mg/kg/min,
with each dose administered for 40 min; n¼ 8), were infused
into the right renal artery in WKY rats maintained on low-
sodium (0.025% NaCl), normal sodium (1% NaCl), or high-
sodium (6% NaCl) diet for 21 days. The intrarenal arterial
infusion of the vehicle into the right kidney had no effect on
blood pressure, urine flow (V), fractional sodium excretion
(FENa), absolute sodium excretion (UNaV), potassium excretion
(UKV), or glomerular filtration rate (GFR) (Table 1). In WKY
rats on low-salt diet, PD128907 increased V, UNaV, and UKV,
and tended to increase FENa without affecting GFR (Table 2).
In WKY rats on normal or high-salt diet, PD128907 increased
V, UKV, UNaV, and FENa (Tables 3 and 4). The absolute increase
in UNaV with PD128907 was greater in rats on high salt than on
a normal or low-salt diet, but the percentage increases were the
same.
We next studied the effect of the intrarenal infusion of
PD128907 (0.5, 1.0, 5.0, and 10.0 mg/kg/min) in SHRs on
high-salt diet. PD128907 had no effect on blood pressure,
GFR, V, UKV, UNaV, or FENa in SHRs (Table 5; Figure 2a). We
also studied the effect of PD128907 (1.0 mg/kg/min) on renal
function in SHRs on normal salt diet and found that
PD128907 also had no effect blood pressure, GFR, V, UKV,
UNaV, or FENa at the concentration of PD128907 with
1.0 mg/kg/min (Table 6; Figure 2b).
To determine the specificity of the D3 receptor agonist
(PD128907) on sodium excretion, a D3 receptor antagonist
(GR103691, which has been reported to be active in vivo) was
used. GR103691, infused at 1.0 mg/kg/min, did not affect V,
UNaV, FENa, or GFR in WKY rats. However, GR103691
blocked the PD128907 (1.0 mg/kg/min)-mediated increase in
V, UNaV, and FENa (Figure 3a).
To determine if there was any systemic effect of the drugs
selectively infused into the right renal artery, sodium
excretion from the left kidney was also measured. We found
that the renal function, including sodium excretion, in the
left unperfused kidney was not altered by any of the drug
treatments (Figure 3b).
Blockade of ETB receptors attenuates D3
receptor-mediated sodium excretion in WKY rats
We next studied the in vivo interaction between D3 and ETB
receptors in WKY rats. The ETB receptor antagonist, BQ788
(5.0mg/kg/min) did not significantly affect UNaV, but partially
blocked the natriuretic effect of PD128907, suggesting that a
renal D3/ETB receptor interaction played a role in the D3
receptor-mediated natriuresis in WKY rats (Figure 3a).
Stimulation of D3 receptors increases the internalization
of ETB receptors and intracellular D3/ETB colocalization
in WKY rat RPT cells, but not in SHR cells
To determine a mechanism for the observed difference in the
natriuretic response upon D3 receptor activation in WKY and
SHRs, the distribution of both D3 and ETB receptors and
their colocalization were evaluated by confocal microscopy.
In the basal state in WKY rat cells, the D3 receptor was found
in both the plasma membrane and cytoplasm, whereas the
ETB receptor was confined mainly in the plasma membrane.
Treatment with the D3 receptor agonist PD128907 promoted
the internalization of both D3 and ETB receptors and
increased its intracellular colocalization with D3 receptors
(Table 7). Treatment with the D3 receptor antagonist
GR103691, ETB receptor antagonist BQ788, or with
PD128907 in combination with either antagonist, failed to
drive the ETB receptors intracellularly in WKY rat cells
(Figure 4a).
In SHR RPT cells, the D3 receptor was found in both the
plasma membrane and cytoplasm under basal condition.
However, the ETB receptor was expressed exclusively in the
cytoplasm, in contrast to its exclusive expression in the
plasma membrane in WKY rat RPT cells. D3 receptor
stimulation, as with the other treatments, did not alter the
cytoplasmic location of both D3 and ETB receptors and failed
to promote the colocalization of the receptors (Table 7). There
was some colocalization between these proteins just below the
cell membrane in the basal state and was not altered by D3
receptor stimulation, alone (Table 7) or with ETB inhibition,
presumably arising from the more scattered distribution of
the D3 receptor within the cytoplasm (Figure 4b).
Kidney International (2008) 74, 750–759 751
C Zeng et al.: D3 receptor and ETB receptors interaction in kidney o r i g i n a l a r t i c l e
DISCUSSION
The natriuretic effect of dopamine is best manifested under
conditions of moderate sodium intake in normotensive
humans,19,20 dogs,21 WKY rats,22,23 and Dahl salt-resistant
rats.24 Disruption of the D3 receptor gene in mice impairs
their ability to excrete a sodium load.11 Previous studies
have found that 7-OH-DPAT, a D3 receptor agonist, induces
a natriuresis in normotensive Dahl salt-sensitive rats
on normal sodium diet but not in hypertensive Dahl salt-
sensitive rats on high-sodium diet.25,26 The diminished
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Figure 1 | D3 and ETB receptor staining in the rat kidneys. (a, b) D3 receptor is located in RPTs from WKY rats (a) and SHRs (b). No staining
is seen when the D3 receptor antibody was preadsorbed with the immunizing peptide. (c, d) ETB receptor is located in RPTs from WKY
rats (c) and SHRs (d). No staining is seen when the ETB receptor antibody was preadsorbed with the immunizing peptide. These
studies were performed at least three times. (e) D3 and ETB receptor colocalization in kidneys from WKY rats. Colocalization appears
as yellow after merging the images of fluorescein isothiocyanate-tagged ETB receptor (green) and Alexa 568-tagged D3 receptor (red).
No staining is seen without the antibodies (DIC). DIC, differential interference contrast.
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natriuretic response to D3 receptor stimulation in the hyper-
tensive Dahl salt-sensitive rat is associated with decreased
3[H]-7-OH-DPAT binding to renal membranes.25,26 How-
ever, the same group did not find a strain-dependent effect
of 7-OH-DPAT in WKY rats and SHRs.27 The interpretation
of this study, however, is confounded by the systemic
administration of 7-OH-DPAT; activation of D3 receptors
and non-D3 dopamine receptors outside the kidney makes
interpretation difficult. For example, activation of D3 recep-
tors could decrease renin production in tissues other than the
kidney, decrease aldosterone secretion, or inhibit sympathetic
activity resulting in a decrease in blood pressure.1–4 To
Table 1 | Effect of vehicle on renal function in the infused right kidney of WKY rats
Systolic (mm Hg) MAP (mm Hg) Diastolic (mm Hg) V (ll/min) FENa (%) UNaV (nEq/min) UKV (nEq/min) GFR (ml/g kidney per min)
CTRL 135.17±6.94 109.33±2.36 93.33±5.42 3.80±0.54 0.18±0.02 325±54 557±89 0.99±0.06
w/P 135.50±6.25 108.50±3.77 88.33±4.15 3.87±0.46 0.20±0.03 312±55 622±90 0.98±0.06
w/P 131.50±3.97 105.50±2.90 86.00±3.20 3.60±0.33 0.23±0.05 299±53 583±94 0.98±0.05
w/P 131.50±4.72 106.67±3.83 88.83±3.91 4.08±0.64 0.22±0.03 332±69 681±122 1.08±0.07
w/P 132.00±3.30 109.00±2.90 91.00±3.40 4.71±0.69 0.29±0.06 404±73 874±100 1.04±0.07
w/P 124.17±1.85 103.00±2.02 86.00±2.31 4.65±0.67 0.27±0.05 433±107 835±160 0.98±0.04
Recovery 119.83±1.19 100.00±2.31 84.50±2.32 5.07±0.60 0.31±0.06 436±102 856±143 0.98±0.04
FENa, fractional Na excretion; GFR, glomerular filtration rate; MAP, mean arterial pressure; period CTRL is baseline (vehicle infusion), periods w/P are the placebo (vehicle)
infusion periods, and period recovery is the recovery period (vehicle infusion); UKV, urine K excretion; UNaV, urine Na excretion; V, urine flow; WKY rat, Wistar–Kyoto rat (body
wt 361±13 g, n=6).
Table 2 | Effect of PD 128907 (D3 agonist) on renal function in the infused right kidney of WKY rats on low-salt diet
Systolic (mm Hg) MAP (mm Hg) Diastolic (mm Hg) V (ll/min) FENa (%) UNaV (nEq/min) UKV (nEq/min) GFR (ml/g kidney/min)
CTRL 132.25±1.37 107.37±2.34 94.87±3.00 3.42±0.31 0.04±0.003 58±3.0 549±66 0.95±0.05
0.5 PD 134.12±1.18 106.87±3.09 93.12±4.21 4.47±0.35 0.04±0.004 67±8.0 909±127 1.19±0.08
1.0 PD 131.25±2.16 105.12±2.59 91.75±3.51 5.46±0.76 0.05±0.014 96±35.1 1103±255 1.18±0.11
5.0 PD 131.25±1.92 103.50±1.51 89.50±1.72 6.44±0.92* 0.09±0.041 159±75.4* 1200±237* 1.13±0.08
10.0 PD 127.37±4.14 101.12±2.71 87.87±2.64 6.46±1.58* 0.12±0.057 225±135.1* 995±207* 1.00±0.10
Recovery 125.16±5.76 98.67±3.59 86.00±3.24 7.02±1.09* 0.19±0.115 324±171.2* 1198±278* 1.09±0.07
ANOVA, analysis of variance; FENa, fractional Na excretion; GFR, glomerular filtration rate; MAP, mean arterial pressure; period CTRL is the baseline (vehicle infusion); periods
0.5 PD, 1.0 PD, 5.0 PD, and 10.0 PD are with infusion of PD 128907 at dosages of 0.5, 1.0, 5.0, and 10.0 mg/kg/min; period recovery is the recovery period (vehicle infusion);
UKV, urine K excretion; UNaV, urine Na excretion; V, urine flow; WKY rat, Wistar–Kyoto rat (body wt 433±24 g, n=8).
*Po0.05 vs CTRL, repeated measures ANOVA (ANVR), Duncan’s test.
Table 3 | Effect of PD 128907 (D3 agonist) on renal function in the infused right kidney of WKY rats on normal salt diet
Systolic (mm Hg) MAP (mm Hg) Diastolic (mm Hg) V (ll/min) FENa (%) UNaV (nEq/min) UKV (nEq/min) GFR (ml/g kidney/min)
CTRL 132.25±1.31 110.00±2.12 99.25±3.12 4.45±0.27 0.06±0.005 115±1.9 716±60 1.23±0.16
0.5 PD 134.25±1.65 104.00±2.54 89.25±2.56 5.85±0.94 0.08±0.011 163±12.9 1085±153 1.22±0.09
1.0 PD 127.75±4.82 100.25±5.76 88.00±7.56 7.12±0.64* 0.09±0.015* 199±39.1 1384±86* 1.34±0.12
5.0 PD 130.50±4.92 102.50±6.38 88.50±7.69 8.25±0.75* 0.11±0.008* 252±27.1* 1756±114* 1.31±0.11
10.0 PD 127.50±6.29 95.75±6.79 79.75±7.12 8.30±0.25* 0.17±0.021* 334±53.1* 1637±06* 1.16±0.07
Recovery 127.75±7.02 96.75±7.43 81.25±7.64 7.94±0.43* 0.25±0.009* 392±59.9* 1538±213* 0.92±0.08
ANOVA, analysis of variance; FENa, fractional Na excretion; GFR, glomerular filtration rate; MAP, mean arterial pressure; period CTRL is the baseline (vehicle infusion); periods
0.5 PD, 1.0 PD, 5.0 PD, and 10.0 PD are with infusion of PD 128907 at dosages of 0.5, 1.0, 5.0, and 10.0 mg/kg/min; period recovery is the recovery period (vehicle infusion);
UKV, urine K excretion; UNaV, urine Na excretion; V, urine flow; WKY rat, Wistar–Kyoto rat (body wt 435±23 g, n=4).
*Po0.05 vs CTRL, repeated measures ANOVA (ANVR), Duncan’s test.
Table 4 | Effect of PD 128907 (D3 agonist) on renal function in the infused right kidney of WKY rats on high-salt diet
Systolic (mm Hg) MAP (mm Hg) Diastolic (mm Hg) V (ll/min) FENa (%) UNaV (nEq/min) UKV (nEq/min) GFR (ml/g kidney/min)
CTRL 139.25±3.41 110.00±3.42 96.71±4.95 5.25±0.93 0.35±0.08 924±199 763±211 1.14±0.07
0.5 PD 136.85±1.81 109.71±3.10 97.85±4.57 7.23±1.40 0.48±0.16 1241±330 1122±253* 1.19±0.13
1.0 PD 136.71±1.68 107.28±2.03 92.71±2.79 8.74±1.52* 0.66±0.20 1768±551 1339±206* 1.09±0.14
5.0 PD 135.28±1.81 108.86±3.39 95.00±4.81 9.94±2.02* 0.71±0.22 2092±702* 1503±227* 1.16±0.11
10.0 PD 134.43±1.25 107.71±2.68 94.28±3.67 9.81±1.25* 0.96±0.20* 2266±516* 1387±190* 0.99±0.11
Recovery 131.14±2.31 104.71±2.25 90.43±2.17 10.38±1.16* 1.20±0.21* 2605±466* 1344±142* 0.94±0.05
ANOVA, analysis of variance; FENa, fractional Na excretion; GFR, glomerular filtration rate; MAP, mean arterial pressure; period CTRL1 is the baseline (vehicle infusion); periods
0.5 PD, 1.0 PD, 5.0 PD, and 10.0 PD are with infusion of PD 128907 at dosages of 0.5, 1.0, 5.0, and 10.0 mg/kg/min; period recovery is the recovery period (vehicle infusion);
UKV, urine K excretion; UNaV, urine Na excretion; V, urine flow; WKY rat, Wistar–Kyoto rat (body wt 438±20 g, n=7).
Data are expressed as mean±s.e.
*Po0.05 vs CTRL repeated measures ANOVA (ANVR), Duncan’s test.
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overcome these limitations, we studied the renal effects of
another selective D3 receptor agonist, PD128907, which may
be more selective for the D3 receptor than 7-OH-DPAT,
infused directly into the right renal artery, through the right
suprarenal artery in WKY rats and SHRs on low-, normal,
and high-salt diet. Activation of D3 receptor with PD128907
induces natriuresis in WKY rats on low-, normal, or high-
NaCl diet. In contrast, the effect of PD128907 on sodium
excretion is impaired in SHRs fed on normal or high-salt diet.
Endothelin B receptors, which are expressed in RPTs,
medullary thick ascending limbs of Henle, and collecting
ducts of the kidney, have been shown to affect sodium trans-
port in vivo and in vitro.14,28,29 An inhibitory effect of the
ETB receptor on ion and water transport in the renal medulla
has been reported.6,15,30 However, no effect, and inhibitory
and stimulatory effects have been reported in the RPT.15,30–33
Short-term stimulation of ETB receptors in opossum kidney
cells, a proximal tubular cell line, activates the sodium
hydrogen exchanger, NHE3.33 However, a 6-h exposure of
these opossum kidney cells to endothelin-1 inhibits NHE3
expression and activity, through ETB receptors.34
The mechanisms underlying the D3 receptor-mediated
natriuresis and diuresis are not completely understood. We
have suggested that the D3 receptor may interact with other
G-protein-coupled receptors (GPCRs) to increase sodium
excretion.4 There are synergistic effects between renal D1 and
D3 receptors,
12 and antagonistic effects between D3 and AT1
receptors on their expressions and blood pressure regula-
tion.35 Our current study shows that an ETB receptor
antagonist, by itself, does not significantly affect sodium
excretion but partially blocks the natriuretic effect of a D3
receptor agonist in WKY rats, indicating that the natriuretic
and diuretic effects of D3 receptor are, in part, mediated by a
mechanism involving ETB receptors. However, the interac-
tion between D3 and ETB receptors is different between WKY
rats and SHRs; the D3 receptor-mediated natriuresis in SHRs
is impaired.
The mechanism(s) of the impaired D3 receptor-mediated
natriuresis in SHRs is not completely understood. Our
previous study showed that D3 receptor expression in the
renal cortical membrane and RPT cells is decreased in SHRs
relative to those from WKY rats.12 To study another
mechanism that may explain the difference in the natriuretic
response to D3 receptor stimulation between WKY rats and
SHRs, the cellular distribution of D3 and ETB receptors in
rodent RPT cells was ascertained by confocal microscopy.
Our study shows that both D3 and ETB receptors are found
in the plasma membrane and cytoplasm in WKY rat RPT
cells at the basal state, indicating that ETB receptors are
accessible for trans-regulation by agonist-activated mem-
brane D3 receptors. Indeed, agonist stimulation of D3
receptors promotes the internalization of both D3 and ETB
Table 5 | Effect of PD 128907 (D3 agonist) on renal function in the infused right kidney of SHR on high-salt diet
Systolic (mm Hg) MAP (mm Hg) Diastolic (mm Hg) V (ll/min) FENa (%) UNaV (nEq/min) UKV (nEq/min) GFR (ml/g kidney/min)
CTRL 213.00±4.51 182.00±5.19 166.33±6.17 3.48±0.75 0.13±0.008 220±23.6 292±123 1.04±0.03
0.5 PD 211.00±5.13 180.33±6.01 165.33±6.96 3.29±0.65 0.08±0.010 171±31.1 409±158 1.28±0.02
1.0 PD 204.00±2.52 171.33±0.33 154.67±0.88 3.31±0.67 0.10±0.025 178±51.6 479±54 1.09±0.01
5.0 PD 204.00±5.29 172.00±6.56 155.67±7.17 3.38±0.58 0.08±0.027 161±17.1 643±193* 1.35±0.25
10.0 PD 202.33±1.45 171.33±3.18 155.33±4.81 3.51±0.43 0.14±0.034 240±39.4 675±69* 1.09±0.19
Recovery 201.66±0.67 170.33±2.33 154.67±3.53 3.64±0.44 0.16±0.033 242±51.9 670±207* 0.97±0.05
ANOVA, analysis of variance; FENa, fractional Na excretion; GFR, glomerular filtration rate; MAP, mean arterial pressure; period CTRL is the baseline (vehicle infusion); periods
0.5 PD, 1.0 PD, 5.0 PD, and 10.0 PD are with infusion of PD 128907 at dosages of 0.5, 1.0, 5.0, and 10.0 mg/kg/min; period recovery is the recovery period (vehicle infusion); SHR,
spontaneously hypertensive rat (body wt 373±13 g, n=3); UKV, urine K excretion; UNaV, urine Na excretion; V, urine flow.
*Po0.05 vs CTRL, repeated measures ANOVA (ANVR), Duncan’s test.
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Figure 2 | Effect of the renal infusion of a D3 receptor agonist
on sodium excretion in WKY rats and SHRs. (a) Varying dosages
of the D3 receptor agonist, PD128907 (0.5–10.0 mg/kg/min), were
infused into the right renal artery of rats on high-salt diet.
*Po0.05 vs SHR, #Po0.05 vs control, n¼ 6. There is no error bar
when the symbol is bigger than the error bar. (b) PD128907
(1.0mg/kg/min) was infused into the right renal artery of rats on
normal salt diet. *Po0.05 vs control, #Po0.05 vs WKY rat, n¼ 3.
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receptors, as well as their intracellular colocalization.
However, in the basal state while the D3 receptor is found
in both the plasma membrane and cytoplasm, in SHR RPT
cells, the ETB receptor is found exclusively in the cytoplasm
making the receptor inaccessible to extracellular ligand
stimulation. The intracellular distribution of ETB receptors
may also explain the previously reported inability of the ETB
receptor agonist, BQ3020, to increase ETB protein expression
in SHR RPT cells. The D3 receptor signal transduction
pathway in SHR RPT cells is intact; treatment with the D3
receptor agonist 7-OH-DPAT decreases the activity of NHE3,
one of the downstream effectors of activated D3 receptors,
in SHR cells in a concentration-dependent manner, albeit to
a lesser extent compared to those observed in WKY rats.36
Thus, it is conceivable that the aberrant distribution of the
ETB receptors in SHR cells hinders the access of other
GPCRs, for example, D3 receptors, and extracellular agonists
to trans-regulate and activate other GPCRs, ETB receptor in
this instance.
As observed in other GPCRs, agonist stimulation results
in signal transduction and internalization of the agonist-
occupied GPCR.37,38 This results initially in desensitization
but is required for resensitization, allowing the GPCR to
respond to subsequent agonist stimulation. The decreased
amount of D3 receptors in plasma membrane in SHR
cells (relative to WKY rat cells) and the failure of the few
D3 receptors at the plasma membrane of SHR cells to be
Table 6 | Effect of PD 128907 (D3 agonist) on renal function in the infused right kidney of SHR on normal salt diet
Systolic (mm Hg) MAP (mm Hg) Diastolic (mm Hg) V (ll/min) FENa (%) UNaV (nEq/min) UKV (nEq/min) GFR (ml/g kidney/min)
CTRL 167±11 143±11 123±12 3.32±1.06 0.052±0.019 67±21 442±123 1.21±0.09
w/PD 158±5 121±5 103±7 3.84±1.23 0.041±0.012 70±23 613±113 1.40±0.07
w/PD 163±8 127±5 106±7 3.78±0.73 0.046±0.014 68±25 683±82 1.32±0.13
w/PD 164±6 130±5 107±6 3.39±0.28 0.043±0.015 67±27 690±126 1.38±0.17
w/PD 165±8 130±7 107±6 3.08±0.53 0.057±0.014 68±13 599±164 1.35±0.18
w/PD 171±4 130±7 106±8 2.40±0.11 0.048±0.017 69±25 583±86 1.25±0.16
Recovery 171±9 137±11 109±9 2.50±0.29 0.040±0.016 54±18 545±162 1.31±0.16
FENa, fractional Na excretion; GFR, glomerular filtration rate; MAP, mean arterial pressure; NS, not significant; period CTRL is baseline (vehicle infusion); periods w/PD are the
PD 128907 (1 mg/kg/min) infusion periods; period recovery is the recovery period (vehicle infusion); SHR, spontaneously hypertensive rat (body wt=297±4 g, n=3; UKV, urine K
excretion; UNaV, urine Na excretion; V, urine flow.
Data are expressed as means±s.e. P=NS vs CTRL.
1800
*#
*#
# #
*#
*#
+
+
+ Vehicle
PD
BQ
GR
GR+PD
BQ+PD
Vehicle
PD
BQ
GR
GR+PD
BQ+PD
+
*#&@$
+
*#&@$
+
1600
1400
1200
U
N
a V
 (n
Eq
/m
in)
U
N
a V
 (n
Eq
/m
in)
1000
800
600
400
200
0
1800
1600
1400
1200
1000
800
600
400
200
0
C1 C2 P1
Periods (40 min/period)
P2 P3 P4
C1 C2 P1
Periods (40 min/period)
P2 P3 P4 Recovery
Recovery
Figure 3 | Effects of D3 or/and ETB receptors on sodium
excretion in WKY rats. Effects of vehicle (n¼ 6), D3 receptor
agonist PD128907 (1.0 mg/kg/min; n¼ 6), D3 receptor antagonist
GR103691 (1.0 mg/kg/min; n¼ 4), ETB receptor antagonist BQ788
(5.0mg/kg/min; n¼ 4), or in combination (PD128907þGR103691,
PD128907þ BQ788, n¼ 6/group) on sodium excretion (UNaV)
from the right kidney (a) and left kidney (b) of anesthetized WKY
rats on high-salt diet. During control period 1 (C1), only the
vehicle was infused. During control period 2 (C2), the vehicle was
infused into both the vehicle and PD128907 groups; GR103961
was infused into the GR103961 group and the PD128907þ
GR103961 group; and BQ788 was infused into the BQ788 group
and the PD128907þ BQ788 group. During periods 3–6 (P1, P2, P3,
and P4, respectively), PD128907 was infused into the PD128907
group, PD128907 and GR103961 were co-infused into the
PD128907þGR103691 group, and PD128907 and BQ788 were
co-infused in the PD128907þ BQ788 group. During period 7, only
the vehicle was infused into all groups; this was considered the
recovery period. Data are expressed as mean±s.e. *Po0.05 vs
vehicle, #Po0.05 vs GR, &Po0.05 vs GRþ PD, @Po0.05 vs BQ,
$Po0.05 vs BQþ PD (factorial ANOVA), þPo0.05 vs control
(repeated measures ANOVA), Duncan’s test.
Table 7 | Effect of a D3 receptor agonist on the colocalization
of D3 and ETB receptors in cell membrane, and cytoplasm in
WKY and SHR RPT cells
WKY SHR
Structure Basal PD128907 Basal PD128907
Membrane (%) 37.76±3.00* 10.03±3.13 6.04±1.65 7.02±1.99
Cytoplasm (%) 12.87±2.41 40.95±2.46* 20.01±0.02 21.25±0.64
ANOVA, analysis of variance; ETB, endothelin B; SHR, spontaneously hypertensive rat;
RPT, renal proximal tubule; WKY rat, Wistar–Kyoto rat.
Twenty to forty regions of interest (cell membrane and cytoplasm) per cell (n=3/rat
strain) were randomly selected and the extent of colocalization was determined as
the degree (in %, Metamorph 6.1) of overlap between the fluorescent signals of D3
and ETB receptors. Data are expressed as mean±s.e.m.
*Po0.05 vs others (same subcellular compartment), one-way factorial ANOVA
Scheffe’s test, n=3 experiments.
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internalized following receptor occupation prevent their
resensitization, resulting in decreased agonist responsiveness
of the D3 receptor to current and subsequent stimulation in
SHRs. It is possible that differences in total basal renal
expression of D3 and ETB receptors in WKY rats and SHRs
could also participate in the differential effect of D3 receptor
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Figure 4 | Effect of D3 receptor stimulation on ETB receptor cellular localization in immortalized RPT cells from WKY rats (a) and
SHRs (b). The cells were serum-starved for 1 h and treated with the D3 receptor agonist PD128907, D3 receptor (D3R) antagonist GR103691,
ETB receptor antagonist BQ788, PBS (vehicle), or a combination of D3 receptor agonist with either antagonist for 30 min. Images
obtained by laser scanning confocal microscopy of D3 receptor (pseudocolored red), ETB receptor (green), cell membrane (CM, blue),
and nucleus (magenta) were overlain using Olympus Fluoview FV300 version 3C Acquisition Software. Inset images represent magnified
versions of selected regions of the cell. Colocalization between D3 and ETB receptors is shown in yellow (inset, white arrows), whereas
that of ETB receptor and the cell membrane is in cyan (inset), n¼ 3 independent experiments.
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stimulation in these two rat strains. We have reported that
RPT cell D3 receptor expression is decreased in SHRs, relative
to WKY rats.35 Therefore, a decreased renal D3 expression
and D3 and ETB interaction in SHRs may explain the
decreased natriuretic effect of D3 agonists in this rat strain.
Although the proximal tubule is responsible for most of
sodium reabsorption along the nephron, both D3 and ETB
receptors are present in more distal nephron segments,
for example, medullary collecting duct.14,39–42 Therefore, the
D3-receptor-mediated increase in sodium excretion involving
the ETB receptor may involve nephron sites other than the
proximal tubule.
In summary, we have demonstrated that the renal
activation of the D3 receptor induces natriuresis and diuresis
in WKY rats on low-, normal, or high-NaCl diet. An ETB
receptor antagonist, by itself, has no effect but partially blocks
the natriuretic effect of a D3 receptor agonist in WKY rats. In
contrast, the D3 receptor agonist does not affect sodium
excretion in SHRs. In WKY rat RPT cells, the ETB receptors
are located mainly at plasma membranes and thus are
available for interaction with agonist-activated, membrane-
located D3 receptors. However, under basal conditions,
the ETB receptors in SHR RPT cells are found mainly in
the cytoplasm and are inaccessible to agonist-stimulated,
membrane-located D3 receptors. The aberrant ETB receptor
distribution in the SHR RPT cells may explain, in part, the
impaired ability to excrete a sodium load in spontaneous
hypertension.
MATERIALS AND METHODS
Immunohistochemistry
The rat kidneys were cleared of blood with oxygenated saline and kept
in Histochoice (Amresco, Kaysville, UT, USA) for 1–2 days at 41C.
The samples were embedded in paraffin and 4-mm sections mounted
on slides. Immunostaining was performed, as reported,43,44 using
rabbit anti-rat ETB receptor antibody (Alomone Labs, Jerusalem,
Israel) or rabbit anti-rat D3 receptor antibody at 41C overnight. The
specificity of the antibodies has been proved in our previous
experiments.12,43 Biotinylated anti-rabbit-immunoglobulin-G and
diaminobenzidine detection system (Vectastain ABC Kit; Vector Labs,
Peterborough, UK) were used for color development.44 The samples
were counterstained with hematoxylin. Controls included antibody
preadsorbed with its immunizing peptide.
Biotinylation, confocal microscopy, and quantification of
D3 receptor, and ETB receptor colocalization in rat RPTs
and RPT cells
The kidneys were perfused with saline and flash-frozen in Optimal
Cutting Temperature Compound.44 The frozen kidney sections were
mounted on slides, fixed with cold methanol for 10 min,
permeabilized (0.1% Triton X-100 in phosphate-buffered saline
(PBS)) for 30 min at room temperature, and blocked by 5% normal
goat serum in PBS.
The WKY rat and SHR RPT cells are immortalized cell lines45
and have characteristics similar to freshly obtained RPT brush
border membranes and RPTs, at least with regard to D1 receptors
and their responses to G-protein stimulation.46,47 The WKY rat and
SHR RPT cells (o23 passages) were grown on coverslips to 40–50%
confluence and treated for 30 min with D3 receptor agonist
(PD128907, 106 M), D3 receptor antagonist (GR103691, 10
6
M),
ETB receptor antagonist (BQ788, 106 M), vehicle (PBS), or a
combination of the D3 receptor agonist with either antagonist after
serum starvation for 1 h. The cells were washed three times with
ice-cold PBS and the cell membrane was labeled with the cell-
impermeant EZ-link sulfo-NHS-SS-Biotin (1 mg/ml) for 30 min on
ice. The cells were washed with ice-cold PBS, supplemented with
10 mM glycine, pH 7.0 to stop the reaction and remove the excess
biotin, and then fixed with 4% paraformaldehyde and permeabilized
with 0.05% Triton X-100 in PBS. The RPTs or RPT cells were
double immunostained for D3 receptor and ETB receptor using
monoclonal anti-D3 receptor antibody (1:200; Zymed, South
San Francisco, CA, USA) and the affinity-purified rabbit polyclonal
anti-ETB receptor antibody (1:200), and then with goat anti-mouse
secondary antibody conjugated with Alexa 633 and goat anti-rabbit
secondary antibody conjugated with Alexa 568 (1:200 for each;
Molecular Probes, Carlsbad, CA, USA). After incubating the
cells with FITC-conjugated avidin for 10 min, the cells were washed
with PBS and distilled water before mounting on glass slides using
Vectashield mounting medium with 4,6-diamidino-2-phenylindole.
Nail polish was used as sealant. Images were obtained for D3
receptor (pseudocolored red), ETB receptor (pseudocolored
green), cell membrane (pseudocolored blue), and the nucleus
(pseudocolored magenta) through laser confocal microscopy.
Corresponding images were overlain using the Olympus Fluoview
FV300 version 3C Acquisition Software.35,44 The experiments
were repeated three times. Quantitative analysis of the extent of
colocalization between D3 and ETB receptors in both cells lines
was performed (Metamorph 6.1; Molecular Devices). After subtrac-
tion of background fluorescence and thresholding, 30–40 regions
of interest (cell membrane and cytoplasm) were selected and the
degree (expressed as %) of overlapping signals for each region of
interest was obtained using the ‘colocalization’ application of the
software.
In vivo studies
Male WKY rats and SHRs (Taconic Farms, Germantown, NY, USA),
ranging in age from 9 to 16 weeks and fed low- (0.06%), normal
(0.4%), or high-(6%) sodium diet for 21 days48 prior to the
performance of the experiments, were anesthetized with pento-
barbital (50 mg/kg body wt, intraperitoneally), placed on a heated
table to maintain rectal temperature between 36 and 371C,
and tracheotomized (PE-240). Anesthesia was maintained by the
infusion of pentobarbital at 0.8 mg/100 g body wt per h.12 Catheters
(PE-50) were placed into the external jugular and femoral veins, and
femoral artery. Systemic arterial pressure was monitored electro-
nically (Cardiomax II; Columbus Instruments, Columbus, OH,
USA). Laparotomy was performed, and both the right and left
ureters were catheterized (PE-10). The right renal artery was
exposed, and the right suprarenal artery, which originates from the
right renal artery, was catheterized (PE-10 heat stretched to 180 mm)
and the vehicle (saline) or drugs was infused at a rate of 40 ml/h.12
The duration of the surgical procedures was about 60 min.
Fluid losses during surgery were replaced with 5% albumin at 1%
body weight over 30 min. GFR was determined by the clearance of
[14C]-inulin (NEN, Boston, MA, USA) in normal saline infused at
5 ml/100 g body wt for 30 min, followed by a rate of 0.8 ml/100 g
body wt per h until the end of the experiment, as previously
reported.12 After an equilibration period of 120 min, urine was
collected every 40 min for clearance measurements.
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In vivo studies, groups
Control group. In the control group, normal saline (vehicle)
was infused into the right suprarenal artery.
Dose–response (PD128907) groups. After a baseline period,
the WKY rats (on low-, normal, or high-salt diet) and SHRs
(normal or high-salt diet) were infused, through the right
renal artery, with PD128907 at a dose of 0.5, 1.0, 5.0, and
10.0mg/kg/min.13,35,48,49 Thereafter, the infusate was changed to the
vehicle (recovery period); each period lasted 40 min.
Single-dose infusion groups. The WKY rats were divided into
six groups: (1) vehicle; (2) D3 receptor agonist (PD128907); (3) D3
receptor antagonist (GR103691);50 (4) ETB receptor antagonist
(BQ788);51 (5) combined D3 receptor agonist and antagonist
(PD128907þGR103691); and (6) combined D3 receptor agonist
and ETB receptor antagonist (PD128907þBQ788).
The vehicle group was treated as described for the control group.
For the D3 receptor agonist group, two baseline periods were
obtained. Thereafter, PD128907 was infused (1.0 mg/kg/min) for
four time periods, followed by one recovery period in which the
drug infusion was stopped but the vehicle infusion was continued
for another 40 min.
To determine the effect of blockade of D3 or ETB receptors
on basal renal function, GR103691 (1.0 mg/kg/min) or BQ788
(5.0 mg/kg/min) was infused during the second baseline period and
continued for four periods followed by recovery. To determine the
effect of a D3 receptor blocker on D3 receptor agonist effect,
GR103691 was infused during the second baseline period, and then
co-infused with PD128907 for four time periods, followed by
recovery. To determine the effect of an ETB receptor blocker on D3
receptor agonist effect, BQ788 was infused during the second
baseline period, and then co-infused with PD128907 for four
periods, followed by recovery. During the recovery period, all drug
infusions were stopped and only the vehicle was infused; each period
lasted 40 min.
Blood samples were obtained before starting the infusion of
[14C]-inulin, before the first collection period, and at the end of the
experiment. Radioactivity, and sodium and potassium concentra-
tions in the blood and urine samples were analyzed. The rats were
killed by an overdose of pentobarbital (100 mg/kg body wt).
Statistical analysis
The data are expressed as mean±s.e.m. Comparison within groups
was made by repeated measures analysis of variance (ANOVA) with
Duncan’s or Holm–Sidak test (or paired t-test when only two groups
were compared); comparison among groups was made by one-way
factorial ANOVA with Duncan’s, Holm–Sidak, or Scheffe’s test.
A value of Po0.05 was considered significant.
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